INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.37
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.48

25 Jul
2024

-0.010

OPEN

$2.46

-0.40%

HIGH

$2.50

317,913

LOW

$2.45

TARGET
$2.40 -3.2% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 10.8 7.9 xxx
DPS (cps) xxx 6.0 6.2 xxx
EPS Growth xxx 54.2% - 26.2% xxx
DPS Growth xxx - 14.3% 2.5% xxx
PE Ratio xxx N/A 31.0 xxx
Dividend Yield xxx N/A 2.5% xxx
Div Pay Ratio(%) xxx 55.8% 77.5% xxx

Dividend yield today if purchased 3 years ago: 1.13%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.44

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx10.8
DPS All xxxxxxxxxxxxxxx6.0
Sales/Revenue xxxxxxxxxxxxxxx440.1 M
Book Value Per Share xxxxxxxxxxxxxxx160.1
Net Operating Cash Flow xxxxxxxxxxxxxxx71.4 M
Net Profit Margin xxxxxxxxxxxxxxx5.69 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx6.95 %
Return on Invested Capital xxxxxxxxxxxxxxx3.60 %
Return on Assets xxxxxxxxxxxxxxx3.09 %
Return on Equity xxxxxxxxxxxxxxx6.95 %
Return on Total Capital xxxxxxxxxxxxxxx5.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx17 M
Long Term Debt xxxxxxxxxxxxxxx348 M
Total Debt xxxxxxxxxxxxxxx365 M
Goodwill - Gross xxxxxxxxxxxxxxx444 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx34 M
Price To Book Value xxxxxxxxxxxxxxx2.05

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx44.0 M
Capex % of Sales xxxxxxxxxxxxxxx10.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx342 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx58 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

22/02/2024

3

Neutral

$2.20

-11.29%

Citi found the released interim financials broadly as expected. Integral Diagnostics is in the midst of an organisational restructure, and the margin outlook for H2 remains unchanged, or so it appears.

The broker has slightly lifted estimates, which leads to the target price increasing to $2.20 from $1.95. Neutral rating retained.

Integral Diagnostics took a -$71.5m impairment loss on its NZ business, roughly half of the book value, the broker notes, on lower margin assumptions. This pushed the result into a statutory loss.

Citi analysts were not surprised by the decision, "given the change in competitive landscape witnessed over the past few years".

FORECAST
Citi forecasts a full year FY24 dividend of 6.00 cents and EPS of 8.40 cents.
Citi forecasts a full year FY25 dividend of 6.00 cents and EPS of 10.50 cents.

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

3

xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

19/06/2024

3

Hold

$2.10

-15.32%

In a positive for both parties, according to Canaccord Genuity, Integral Diagnostics has made a takeover/merger proposal bid for peer diagnostic imaging company Capitol Health. It is a 100% scrip merger, which provides 0.12849 Integral shares per Capitol share.

The broker believes the deal is priced fairly and helps mitigate balance sheet pressure for Integral Diagnostics and will drive synergies in what is becoming a more competitive market.

Around -$10m of annual cost synergies are also expected within two years, coming from headcount, indirect procurement, and savings on costs associated with maintaining ASX listing.

The Hold rating and $2.10 target are maintained for Integral Diagnostics.

Jarden

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

IDX STOCK CHART

FNArena News on IDX

1
In Brief: Airlines, Pathology & Seek

Jul 12 2024 - Weekly Reports
2
Weekly Ratings, Targets, Forecast Changes – 28-06-24

Jul 01 2024 - Weekly Reports
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Australian Broker Call *Extra* Edition – Jun 19, 2024

Jun 19 2024 - Daily Market Reports
5
In Brief: Budget 2024/25, Iron Ore & Milk

May 17 2024 - Weekly Reports

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
2
ResMed Silences The Doubters

Apr 29 2024 - Australia
3
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
4
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
5
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
6
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
7
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps
8
ResMed Recovery Turns Into Hollywood Script

Jan 31 2024 - Australia
9
ResMed Makes A Comeback

Jan 29 2024 - Australia
10
ResMed: The Recovery Has Begun

Jan 23 2024 - Technicals